APRINOIA Therapeutics Inc. today announced that they had executed a worldwide 
non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access 
APRINOIA's positron emission tomography (PET) imaging tracer, [18F]-APN-1607, 
for neurodegenerative diseases. This is an extension of a collaboration between 
APRINOIA and Biogen to discover novel PET imaging tracers for visualization and 
quantification of abnormal tau protein accumulation in the brain.

18F-APN-1607 is a new generation tau PET imaging tracer with improved 
selectivity and off-target binding profiles. It is designed to specifically 
recognize tau proteins in their pathological aggregated states. Pathological 
tau proteins are associated with neurodegeneration in Alzheimer's disease (AD) 
and other tau-related brain disorders (tauopathies), including progressive 
supranuclear palsy (PSP), frontotemporal dementia (FTD), chronic traumatic 
encephalopathy (CTE), and corticobasal degeneration (CBD). [18F]-APN-1607 could 
be used to quantify tau burden and visualize distribution of tau abnormality in 
different types of tauopathies, offering broad clinical utilities.

"We are excited to announce our collaboration with Biogen. It has been a 
fruitful collaboration to combine expertise from both companies to advance our 
understanding of [18F]-APN-1607 and to discover next generation imaging 
tracers," said Ming-Kuei Jang, CEO of APRINOIA. "APRINOIA is committed to make 
[18F]-APN-1607 and our other imaging tools available to research and medical 
communities to explore clinical utilities of those tools and facilitate 
clinical research of potential treatments for neurodegenerative diseases."

About APRINOIA

APRINOIA Therapeutics is currently advancing a pipeline featuring diagnostic 
and therapeutic programs, collectively targeting brain disorders associated 
with abnormal accumulation of pathological proteins, including tau and 
alpha-synuclein, from its proprietary small molecule and antibody discovery 
platforms. APRINOIA is committed to building a pipeline of innovative products, 
as well as developing partnership with global and regional pharmaceutical 
companies to accelerate its programs. The company currently has operations in 
Taipei, Suzhou, Shanghai, Tokyo, and Boston.

Contact: Ms. Mingwei Pu, Email: mingwei.pu@aprinoia.com    

SOURCE: APRINOIA Therapeutics